ID   C666-1
AC   CVCL_7949
SY   c666-1; C6661
DR   BTO; BTO:0004805
DR   Cell_Model_Passport; SIDM01988
DR   ChEMBL-Cells; CHEMBL4482988
DR   ChEMBL-Targets; CHEMBL4483231
DR   Cosmic; 1017617
DR   Cosmic; 1301000
DR   PubChem_Cell_line; CVCL_7949
DR   Wikidata; Q54808229
RX   PubMed=10449618;
RX   PubMed=12645650;
RX   PubMed=18196576;
RX   PubMed=23915735;
RX   PubMed=24991015;
RX   PubMed=25787276;
RX   PubMed=26116706;
RX   PubMed=30405107;
CC   Population: Chinese.
CC   Virology: Contains a complete EBV genome (strain C666-1) which has been sequenced (PubMed=23915735; PubMed=25787276).
CC   Doubling time: 3.5 days (PubMed=10449618).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Omics: Transcriptome analysis by RNAseq.
ST   Source(s): PubMed=18196576; PubMed=26116706; PubMed=30405107
ST   Amelogenin: X,Y
ST   CSF1PO: 11,15 (PubMed=26116706)
ST   CSF1PO: 11,15,16 (PubMed=18196576; PubMed=30405107)
ST   D13S317: 8,11
ST   D16S539: 10
ST   D18S51: 16 (PubMed=18196576; PubMed=30405107)
ST   D18S51: 16,17 (PubMed=26116706)
ST   D19S433: 13,15.2
ST   D21S11: 28,29,30.2,31.2 (PubMed=18196576; PubMed=30405107)
ST   D21S11: 29,31.2 (PubMed=26116706)
ST   D2S1338: 16,23
ST   D3S1358: 16,17 (PubMed=18196576; PubMed=30405107)
ST   D3S1358: 17 (PubMed=26116706)
ST   D5S818: 11,12
ST   D7S820: 10,11,12 (PubMed=26116706)
ST   D7S820: 11,12 (PubMed=18196576; PubMed=30405107)
ST   D8S1179: 11,13,14,15 (PubMed=18196576; PubMed=30405107)
ST   D8S1179: 13,15 (PubMed=26116706)
ST   FGA: 21,24 (PubMed=26116706)
ST   FGA: 23,24 (PubMed=18196576; PubMed=30405107)
ST   Penta D: 9,10
ST   Penta E: 11,15
ST   TH01: 6,8
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C3871; Nasopharyngeal carcinoma
DI   ORDO; Orphanet_150; Nasopharyngeal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_M597 ! C666
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 21-03-23; Version: 19
//
RX   PubMed=10449618; DOI=10.1002/(SICI)1097-0215(19990924)83:1<121::AID-IJC21>3.0.CO;2-F;
RA   Cheung S.-T., Huang D.P., Hui A.B.-Y., Lo K.-W., Ko C., Tsang Y.S.,
RA   Wong N., Whitney B.M., Lee J.C.-K.;
RT   "Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring
RT   Epstein-Barr virus.";
RL   Int. J. Cancer 83:121-126(1999).
//
RX   PubMed=12645650; DOI=10.1016/S0165-4608(02)00657-X;
RA   Wong N., Hui A.B.-Y., Fan B.-L., Lo K.-W., Pang E., Leung S.-F.,
RA   Huang D.P., Johnson P.J.;
RT   "Molecular cytogenetic characterization of nasopharyngeal carcinoma
RT   cell lines and xenografts by comparative genomic hybridization and
RT   spectral karyotyping.";
RL   Cancer Genet. Cytogenet. 140:124-132(2003).
//
RX   PubMed=18196576; DOI=10.1002/ijc.23374;
RA   Chan S.Y.-Y., Choy K.-W., Tsao S.-W., Tao Q., Tang T., Chung G.T.-Y.,
RA   Lo K.-W.;
RT   "Authentication of nasopharyngeal carcinoma tumor lines.";
RL   Int. J. Cancer 122:2169-2171(2008).
//
RX   PubMed=23915735; DOI=10.1186/1750-9378-8-29;
RA   Tso K.K.-Y., Yip K.Y.-L., Mak C.K.-Y., Chung G.T.-Y., Lee S.-D.,
RA   Cheung S.-T., To K.-F., Lo K.-W.;
RT   "Complete genomic sequence of Epstein-Barr virus in nasopharyngeal
RT   carcinoma cell line C666-1.";
RL   Infect. Agents Cancer 8:29.1-29.4(2013).
//
RX   PubMed=24991015; DOI=10.1128/JVI.01457-14;
RA   Strong M.J., Baddoo M., Nanbo A., Xu M., Puetter A., Lin Z.;
RT   "Comprehensive RNA-seq analysis reveals contamination of multiple
RT   nasopharyngeal carcinoma cell lines with HeLa cell genomes.";
RL   J. Virol. 88:10696-10704(2014).
//
RX   PubMed=25787276; DOI=10.1128/JVI.03614-14;
RA   Palser A.L., Grayson N.E., White R.E., Corton C., Correia S.,
RA   Ba Abdullah M.M., Watson S.J., Cotten M., Arrand J.R., Murray P.G.,
RA   Allday M.J., Rickinson A.B., Young L.S., Farrell P.J., Kellam P.;
RT   "Genome diversity of Epstein-Barr virus from multiple tumor types and
RT   normal infection.";
RL   J. Virol. 89:5222-5237(2015).
//
RX   PubMed=26116706; DOI=10.1096/fj.14-266718;
RA   Ye F., Chen C.-G., Qin J., Liu J., Zheng C.-Y.;
RT   "Genetic profiling reveals an alarming rate of cross-contamination
RT   among human cell lines used in China.";
RL   FASEB J. 29:4268-4272(2015).
//
RX   PubMed=30405107; DOI=10.1038/s41467-018-06889-5;
RA   Lin W.-T., Yip Y.-L., Jia L., Deng W., Zheng H., Dai W., Ko J.M.-Y.,
RA   Lo K.-W., Chung G.T.-Y., Yip K.Y.-L., Lee S.-D., Kwan J.S.-H., Zhang J.,
RA   Liu T.-F., Chan J.Y.-W., Kwong D.L.-W., Lee V.H.-F., Nicholls J.M.,
RA   Busson P., Liu X.-F., Chiang A.K.-S., Hui K.-F., Kwok H., Cheung S.-T.,
RA   Cheung Y.-C., Chan C.-K., Li B., Cheung A.L.-M., Hau P.-M., Zhou Y.,
RA   Tsang C.-M., Middeldorp J.M., Chen H.-L., Lung M.L., Tsao S.-W.;
RT   "Establishment and characterization of new tumor xenografts and cancer
RT   cell lines from EBV-positive nasopharyngeal carcinoma.";
RL   Nat. Commun. 9:4663.1-4663.17(2018).
//